The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Exciting results from CARTITUDE-1: anti-BCMA CAR-T for MM
Ciltacabtagene autoleucel (cilta-cel; formerly JNJ-4528) is CAR T-cell therapy containing two BCMA-targeting single-domain antibodies designed to confer avidity. Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, discusses the results from the CARTITUDE-1 trial (NCT03548207), a Phase Ib/II study of cilta-cel in patients with relapsed and/or refractory multiple myeloma (MM). Dr Berdeja highlights the very exciting results, including measurable residual disease (MRD) negativity in all evaluable patients tested and a manageable safety profile. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
